Sumitomo Pharma Co Ltd 2020 IR
The report highlights Sumitomo Dainippon Pharma's strategic alliance with Roivant Sciences, which expanded its pipeline with late-stage assets like relugolix and vibegron. It outlines the company's CSR-based management, focusing on its top priority Sustainable Development Goals and establishing qualitative targets for materiality. The company also advanced its regenerative medicine and cell therapy field, notably with the SMaRT manufacturing plant. Financially, the company achieved a revenue of 482,762 million yen for fiscal 2019, with overseas sales accounting for 63.8%.
Company: Sumitomo Pharma Co Ltd
Sector: Health Care
Country: Japan
Year: 2020
Type: IR
Pages: 158
Sumitomo Pharma Co Ltd
Integrated Report
The report highlights Sumitomo Dainippon Pharma's strategic alliance with Roivant Sciences, which expanded its pipeline with late-stage assets like relugolix and vibegron. It outlines the company's CSR-based management, focusing on its top priority Sustainable Development Goals and establishing qualitative targets for materiality. The company also advanced its regenerative medicine and cell therapy field, notably with the SMaRT manufacturing plant. Financially, the company achieved a revenue of 482,762 million yen for fiscal 2019, with overseas sales accounting for 63.8%.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2019
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Employees